Robert W. Baird Lowers Vor Biopharma (NYSE:VOR) Price Target to $14.00

Vor Biopharma (NYSE:VOR) had its price target trimmed by Robert W. Baird from $22.00 to $14.00 in a report published on Friday morning,Benzinga reports. The firm currently has an outperform rating on the stock.

VOR has been the topic of several other reports. Barclays dropped their price objective on shares of Vor Biopharma from $10.00 to $3.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 14th. JMP Securities reiterated a “market outperform” rating and set a $12.00 price objective on shares of Vor Biopharma in a research note on Friday, September 6th. Finally, HC Wainwright reiterated a “buy” rating and set a $17.50 price objective on shares of Vor Biopharma in a research note on Friday, September 6th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus target price of $11.36.

Vor Biopharma Stock Up 5.4 %

Shares of VOR stock opened at $1.01 on Friday. The company’s fifty day simple moving average is $0.80 and its 200-day simple moving average is $1.06. The firm has a market cap of $69.08 million, a PE ratio of -0.61 and a beta of -0.40. Vor Biopharma has a 12 month low of $0.63 and a 12 month high of $3.14.

Vor Biopharma (NYSE:VOR) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.40) EPS for the quarter, hitting analysts’ consensus estimates of ($0.40). On average, equities analysts predict that Vor Biopharma will post -1.51 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Acadian Asset Management LLC raised its holdings in Vor Biopharma by 51.4% during the 2nd quarter. Acadian Asset Management LLC now owns 81,305 shares of the company’s stock worth $79,000 after purchasing an additional 27,597 shares during the last quarter. Hsbc Holdings PLC raised its holdings in Vor Biopharma by 177.0% during the 2nd quarter. Hsbc Holdings PLC now owns 49,038 shares of the company’s stock worth $51,000 after purchasing an additional 31,333 shares during the last quarter. Exchange Traded Concepts LLC raised its holdings in Vor Biopharma by 40.8% during the 3rd quarter. Exchange Traded Concepts LLC now owns 165,805 shares of the company’s stock worth $116,000 after purchasing an additional 48,017 shares during the last quarter. Cubist Systematic Strategies LLC bought a new position in Vor Biopharma during the 2nd quarter worth approximately $53,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in Vor Biopharma during the 2nd quarter worth approximately $63,000. Institutional investors own 97.29% of the company’s stock.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.